More and more countries are completing their epidemiological mapping of trachoma in suspected
endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of
“trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass... drug
administration (MDA) is normally at the district level and targets the whole population with Zithromax®
tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5
years of age; and tetracycline eye ointment 1% for infants up to 6 months old.
more
Biosafety involves the implementation of containment principles, technologies and practices to prevent unintentional exposure to biological agents. Biosecurity involves the protection, control and accountability of biological materials and information related to these materials and dualuse research,... to prevent their unauthorized access, loss, theft, misuse, diversion or intentional release.
more
Good practice examples from India
A discussion tool on improving access & inclusion for displaced persons with disabilities
Immunisation - the safest way to protect your child
2010/4 Vol. 22 | pages 425 à 435
ISSN 0995-3914
La reproduction ou représentation de cet article, notamment par photocopie, n'est autorisée que dans les
limites des conditions générales d'utilisation du site ou, le cas échéant, des conditions générales de la
licence souscrite par votr...e établissement. Toute autre reproduction ou représentation, en tout ou partie,
sous quelque forme et de quelque manière que ce soit, est interdite sauf accord préalable et écrit de
l'éditeur, en dehors des cas prévus par la législation en vigueur en France. Il est précisé que son stockage
dans une base de données est également interdit.
more
This guidance aims to assist leaders in the development or revision of humanitarian-sector contributions to district-level pandemic preparedness and response planning. It is directly linked to H2P guidance for national-level planning.
This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing thirty key questions about PrEP and how it might be implemented in the UK.
May 2018
HIV i-Base
ISSN 1475-2077 www.i-Base.info
Watch for out-of-date information
First questions
You and your doctor Resistance and adherence Treatment choices
Cureus 2024 Jan 16;16(1):e52358. doi: 10.7759/cureus.52358